Abby Hardy, Author at BioTuesdays

Developments

Esperion presents positive Phase 3 NEXLETOL data

Esperion (NASDAQ: ESPR) presented positive pooled results from four Phase 3 NEXLETOL trials at the virtual American Heart Association scientific sessions. NEXLETOL, or bempedoic acid, is a non-statin, low-density...

November 13, 2020

Developments

Albireo Pharma presents positive Phase 3 odevixibat data

Albireo Pharma (NASDAQ:ALBO) presented positive results from two Phase 3 trials of odevixibat at the American Association for the Study of Liver Diseases meeting. Odevixibat is an ileal bile acid transport inhibitor...

November 13, 2020

Developments

Annexon initiates Phase 2 Huntington’s disease trial

Annexon (NASDAQ:ANNX) launched a Phase 2 trial evaluating ANX005 for the treatment of Huntington’s disease. ANX005 is a monoclonal antibody designed to inhibit the complement protein, C1q. “Huntington’s disease is a...

November 13, 2020

Developments

Hepion to present positive CRV431 findings at liver conference

Hepion Pharmaceuticals (NASDAQ:HEPA) will present positive findings from an expanded study of CRV431 at The Liver Meeting Digital Experience 2020 on Nov. 13. The poster presentation will review a study in which...

November 12, 2020

Developments

Surface Oncology gets FDA fast track designation for hepatocellular carcinoma

Surface Oncology’s (NASDAQ:SURF) SRF388 received FDA fast track designation for the treatment of hepatocellular carcinoma in patients who have previously been treated with standard therapies. SRF388 is a fully human...

November 11, 2020

Developments

Lineage Cell Therapeutics completes enrollment in Phase 1/2a dry AMD trial

Lineage Cell Therapeutics (NASDAQ:LCTX) completed enrollment in its Phase 1/2a trial evaluating OpRegen for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy. OpRegen is injected into...

November 11, 2020

Developments

IntelGenx receives U.S. patent for novel oral film dosage technology

IntelGenx (TSXV:IGX; OTCQB:IGXT) received a patent from the U.S. Patent and Trademark Office, covering a novel oral film dosage technology platform for modulating the absorption profile of a sublingually- or buccally...

November 11, 2020

Developments

Five Prime bemarituzumab meets all efficacy endpoints in Phase 2 gastric cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported positive topline results from its Phase 2 trial evaluating bemarituzumab, in combination with chemotherapy, in patients with fibroblast growth factor receptor 2b-positive...

November 10, 2020

Developments

Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

Lumos Pharma (NASDAQ:LUMO) launched a Phase 2b trial evaluating LUM-201 for the treatment of pediatric growth hormone deficiency (PGHD). PGHD is typically caused by the pituitary gland’s inability to make sufficient...

November 10, 2020

Developments

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...

November 10, 2020

Author - Abby Hardy

Esperion presents positive Phase 3 NEXLETOL data

Albireo Pharma presents positive Phase 3 odevixibat data

Annexon initiates Phase 2 Huntington’s disease trial

Hepion to present positive CRV431 findings at liver conference

Surface Oncology gets FDA fast track designation for hepatocellular carcinoma

Lineage Cell Therapeutics completes enrollment in Phase 1/2a dry AMD trial

IntelGenx receives U.S. patent for novel oral film dosage technology

Five Prime bemarituzumab meets all efficacy endpoints in Phase 2 gastric cancer trial

Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

General

More